Moderna (MRNA, $58.57) might be delaying start of Phase 3 trial of covid-19 vaccine

Biotech company Moderna   has reportedly delayed the start of a Phase III trial of its coronavirus vaccine.

The healthcare website Stat News reported that Moderna was making changes to the trial plan, and therefore the start date of the Phase III study has been pushed back, according to investigators who did not want to be named.

“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator said, according to Stat News. “As best I can tell, they’re close to being on target for that.”

Moderna wrote on Twitter that "the trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial."

According to Tickeron, MRNA's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line

This is a Bearish indicator signaling MRNA's price could decline. Traders may explore shorting the ticker or looking at put options. In 10 of 12 cases where MRNA's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 83%.

Current price $58.57 crossed the support line at $59.87 and is trading between $59.87 support and $57.71 support lines. Throughout the month of 06/02/20 - 07/02/20, the price experienced a -2% Downtrend. During the week of 06/25/20 - 07/02/20, the stock fell -6%.

Technical Analysis (Indicators):

Bearish Trend Analysis

The Stochastic Indicator may be shifting from an Uptrend to a Downtrend. In 16 of 21 cases where MRNA's Stochastic indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 76%.

The Momentum Indicator moved below the 0 level on June 26, 2020. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 13 of 21 cases where MRNA's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 62%

The price moved below its 50-day Moving Average, which indicates a reversal from an Uptrend to a Downtrend. In 5 of 9 cases where MRNA's price crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued Downtrend are 56%.

Following a 3-day Decline, the ticker is projected to fall further. Considering data from situations where MRNA declined for three days, in 77 of 97 cases, the price rose further within the following month. The odds of a continued Downtrend are 79%.

Bullish Trend Analysis

The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 8 of 8 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 90%.

The Aroon Indicator entered an Uptrend today. In 64 of 81 similar cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Fundamental Analysis (Ratings)

Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 64%. During the last month, the daily ratio of advancing to declining volumes was 1.14 to 1.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.21) is normal, around the industry mean (2.02). P/E Ratio (0.00) is within average values for comparable stocks, (64.05). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (4.87). Dividend Yield (0.00) settles around the average of (0.08) among similar stocks. P/S Ratio (201.16) is also within normal values, averaging (1250.07).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume